XpressBioX SRL
The score of XpressBioX shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue -58 % Equity 0 % Total assets -54 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
XpressBioX's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 198,000 € | ||||
| Net result | 74,621 € | ||||
| Equity | €8.90m | ||||
| Cash | 0 € | ||||
| EBITDA | 184,768 € | ||||
| Total assets | €8.92m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 13 Apr 2026
- Year ended 31 Dec 2024filed on 09 Apr 2025
- Year ended 31 Dec 2023filed on 29 May 2024
- Year ended 31 Dec 2022filed on 26 May 2023
- Year ended 31 Dec 2021filed on 06 Jul 2022
XpressBioX's financial analysis
- Solvency99.8%sector median: 46.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of XpressBioX
XpressBioX's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0770.527.814
- VAT number
- BE0770527814
- Peppol
- Registered · 0208:0770527814 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 30 Jun 2021
- Registered office
- 4041 Herstal
- Latest accounts
- 2025 · filed on 13 Apr 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
XpressBioX (SRL) has been based in Herstal since 2021, active in: manufacture of basic pharmaceutical products. For 2025, it reports revenue of 198,000 €, a net profit of 74,621 € and equity of €8.90m. Its solvency stands at 99.8%, above the median of its sector (46.9%).
Companies similar to XpressBioX
Companies in the same business, of comparable size and area, outside its group.
- ATB Therapeutics Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €10.6m
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
- Phoenix Biosciences Manufacture of pharmaceutical preparations Nivelles · balance sheet €8.11m
- Etherna Immunotherapies Research and experimental development on natural sciences and engineering Niel · balance sheet €12.8m
- Shant Biotech Manufacture of basic pharmaceutical products Tubize · balance sheet €11.0m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- Aquilon Pharmaceuticals Research and experimental development on natural sciences and engineering Seraing · balance sheet €11.1m
Frequently asked questions about XpressBioX
What is the revenue of XpressBioX?
According to the 2025 annual accounts filed with the NBB, the revenue of XpressBioX amounts to 198,000 €.
What is the VAT number of XpressBioX?
In Belgium, the VAT number is the company number prefixed with BE: BE0770527814 for XpressBioX, if the company is VAT-registered. Its company number (CBE) is 0770.527.814.
Where is the registered office of XpressBioX?
According to the CBE register, the registered office of XpressBioX is in 4041 Herstal.
What is the equity of XpressBioX?
At the close of the 2025 financial year, the equity of XpressBioX amounts to 8,903,602 €, a solvency of 99.8% of total assets.
Who manages XpressBioX?
The register lists 3 active mandates at XpressBioX. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of XpressBioX
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →